A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Christopher L. Bowlus*, Michael R. Galambos, Richard J. Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo, Paul J. Thuluvath, Cynthia Levy, Mark G. Swain, Guy W. Neff, David A. Sheridan, Carmen M. Stanca, Christoph P. Berg, Aparna Goel, Mitchell L. Shiffman, John M. VierlingPol Boudes, Alexandra Steinberg, Yun Jung Choi, Charles A. McWherter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Downloads (Pure)
Original languageEnglish
Number of pages0
JournalJournal of Hepatology
Volume0
Issue number0
Early online date30 Mar 2022
DOIs
Publication statusPublished - 30 Mar 2022

Cite this